Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764198 in FSGS (pFSGS or TRPC6-related hereditary FSGS)
CTR20260050Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apecotrep in focal segmental glomerulosclerosis (FSGS), sponsored by Boehringer Ingelheim. Started Apr 2026; status: active.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on CTR20260050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260050.